TAK vs. OCUL
Compare and contrast key facts about Takeda Pharmaceutical Company Limited (TAK) and Ocular Therapeutix, Inc. (OCUL).
Performance
TAK vs. OCUL - Performance Comparison
Loading graphics...
TAK vs. OCUL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
TAK Takeda Pharmaceutical Company Limited | 18.79% | 23.18% | -3.12% | -4.87% | 20.08% | -23.45% | -5.18% | 22.48% | -38.84% | 41.29% |
OCUL Ocular Therapeutix, Inc. | -30.23% | 42.15% | 91.48% | 58.72% | -59.68% | -66.33% | 424.05% | -0.75% | -10.56% | -46.83% |
Fundamentals
TAK:
$59.36B
OCUL:
$1.89B
TAK:
$36.10
OCUL:
-$1.38
TAK:
0.01
OCUL:
31.49
TAK:
0.01
OCUL:
2.89
TAK:
$4.49T
OCUL:
$51.95M
TAK:
$2.79T
OCUL:
$45.25M
TAK:
$1.39T
OCUL:
-$258.96M
Returns By Period
In the year-to-date period, TAK achieves a 18.79% return, which is significantly higher than OCUL's -30.23% return. Over the past 10 years, TAK has outperformed OCUL with an annualized return of 1.65%, while OCUL has yielded a comparatively lower -1.51% annualized return.
TAK
- 1D
- 1.37%
- 1M
- -1.23%
- YTD
- 18.79%
- 6M
- 26.50%
- 1Y
- 27.35%
- 3Y*
- 7.79%
- 5Y*
- 3.44%
- 10Y*
- 1.65%
OCUL
- 1D
- 14.46%
- 1M
- -5.26%
- YTD
- -30.23%
- 6M
- -27.54%
- 1Y
- 15.55%
- 3Y*
- 17.14%
- 5Y*
- -13.42%
- 10Y*
- -1.51%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TAK vs. OCUL — Risk / Return Rank
TAK
OCUL
TAK vs. OCUL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Takeda Pharmaceutical Company Limited (TAK) and Ocular Therapeutix, Inc. (OCUL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| TAK | OCUL | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.30 | 0.21 | +1.09 |
Sortino ratioReturn per unit of downside risk | 1.76 | 0.91 | +0.85 |
Omega ratioGain probability vs. loss probability | 1.23 | 1.11 | +0.12 |
Calmar ratioReturn relative to maximum drawdown | 2.24 | 0.20 | +2.03 |
Martin ratioReturn relative to average drawdown | 5.82 | 0.52 | +5.30 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| TAK | OCUL | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.30 | 0.21 | +1.09 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.18 | -0.17 | +0.35 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.07 | -0.02 | +0.09 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.12 | -0.05 | +0.16 |
Correlation
The correlation between TAK and OCUL is 0.16, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Dividends
TAK vs. OCUL - Dividend Comparison
TAK's dividend yield for the trailing twelve months is around 1.74%, while OCUL has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TAK Takeda Pharmaceutical Company Limited | 1.74% | 4.24% | 4.67% | 4.41% | 4.23% | 2.98% | 2.30% | 4.20% | 4.77% | 2.81% | 3.99% | 2.92% |
OCUL Ocular Therapeutix, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
TAK vs. OCUL - Drawdown Comparison
The maximum TAK drawdown since its inception was -54.25%, smaller than the maximum OCUL drawdown of -95.19%. Use the drawdown chart below to compare losses from any high point for TAK and OCUL.
Loading graphics...
Drawdown Indicators
| TAK | OCUL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -54.25% | -95.19% | +40.94% |
Max Drawdown (1Y)Largest decline over 1 year | -12.83% | -57.29% | +44.46% |
Max Drawdown (5Y)Largest decline over 5 years | -30.09% | -89.14% | +59.05% |
Max Drawdown (10Y)Largest decline over 10 years | -54.25% | -90.94% | +36.69% |
Current DrawdownCurrent decline from peak | -18.51% | -80.43% | +61.92% |
Average DrawdownAverage peak-to-trough decline | -23.22% | -76.58% | +53.36% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.94% | 22.71% | -17.77% |
Volatility
TAK vs. OCUL - Volatility Comparison
The current volatility for Takeda Pharmaceutical Company Limited (TAK) is 6.63%, while Ocular Therapeutix, Inc. (OCUL) has a volatility of 19.52%. This indicates that TAK experiences smaller price fluctuations and is considered to be less risky than OCUL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| TAK | OCUL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.63% | 19.52% | -12.89% |
Volatility (6M)Calculated over the trailing 6-month period | 13.96% | 58.02% | -44.06% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.17% | 75.47% | -54.30% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 19.34% | 78.73% | -59.39% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.02% | 80.20% | -57.18% |
Financials
TAK vs. OCUL - Financials Comparison
This section allows you to compare key financial metrics between Takeda Pharmaceutical Company Limited and Ocular Therapeutix, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities